TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04273906

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: End-range mobilization
Description: End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: End-range mobilization
Description: End-range mobilization performed in end-range of the tibiofemoral joints' flexion and extension

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placebo technique
Description: Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo technique
Description: Hands-on technique performed in end-range of the tibiofemoral joints' flexion and extension
Study: NCT02320487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine
Description: Bendamustine was administered as an intravenous infusion at a dose of 90 milligrams per square meter (mg/m\^2) on Days 2 and 3 Cycle 1; and on Days 1 and 2 Cycles 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Obinutuzumab was administered as an intravenous infusion at a dose of 100 milligrams (mg) on Day 1 Cycle 1; at a dose of 900 mg on Day 2 Cycle 1; at a dose of 1000 mg on Days 8 and 15 Cycle 1, and Day 1 Cycles 2-6.
Study: NCT03099720

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: local anesthetic will be given locally at the site of operation to decrease the level of pain after operation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo fluid will be given at the site of operation locally
Study: NCT03553186

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 100 MG/ML
Description: TXA lavage solution (200 cc sterile normal saline + 5 g tranexamic acid 100mg/ml (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after instrumentation. Excess solution will be suctioned away using a non-cell saver suction.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo solution (200 cc sterile normal saline + placebo TXA ampule (50cc)) will be poured into the surgical field and left in contact for five minutes. This will occur after pedicle screw instrumentation. Excess solution will be suctioned away using a non-cell saver suction.
Study: NCT01195337

Intervention type: BEHAVIORAL
Intervention: PA Prescription Plan
Description: Exercise program and instructions.

Intervention type: DEVICE
Intervention: Pedometer
Description: Step monitor for individual PA progress.

Intervention type: BEHAVIORAL
Intervention: Newsletters
Description: 4 Newsletters with topics based on PA progression phases of adoption and maintenance.
Study: NCT03313050

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Multivalent
Description: Pneumococcal conjugate vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Tdap
Description: Tetanus, diphtheria, acellular pertussis vaccine

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: polysaccharide
Description: 23-valent pneumococcal polysaccharide vaccine
Study: NCT02722681

Intervention type: PROCEDURE
Intervention: Blood and urine sampling
Description: Collection of blood and urine samples taken during usual clinical management

Intervention type: PROCEDURE
Intervention: Blood and urine sampling
Description: Collection of blood and urine samples taken during usual clinical management

Intervention type: PROCEDURE
Intervention: Blood and urine sampling
Description: Collection of blood and urine samples taken during usual clinical management

Intervention type: PROCEDURE
Intervention: Cerebrospinal fluid sampling
Description: Collection of cerebrospinal fluid samples taken during usual clinical management

Intervention type: PROCEDURE
Intervention: Cerebrospinal fluid sampling
Description: Collection of cerebrospinal fluid samples taken during usual clinical management
Study: NCT00836134

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: rectus sheath block
Description: ultrasound-guided rectus sheath block using 0.2ml/kg 0.25% bupivacaine bilaterally prior to skin incision

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: local anesthetic infiltration
Description: Wound infiltration using 0.4ml/kg 0.25% bupivacaine by the surgeon at the end of surgery
Study: NCT01461174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 200 mg tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil
Description: Donepezil or placebo, 5 mg tablet one per day, 15 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Memantine
Description: Memantine or placebo, 10 mg tablet one per day, 15 days
Study: NCT03915145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Kinesio tape application
Description: Kinesio tape application will be performed.Taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Kinesio tape application
Description: Sham kinesio tape application will be performed. Sham taping is carried out from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins

Intervention type: OTHER
Group type: OTHER
Intervention: No intervention
Description: The natural process will be followed from the estimated day of ovulation (cycle length in days minus 14) until the next menstrual period begins
Study: NCT04156555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin-Clavulanate 875 Mg-125 Mg Oral Tablet
Description: Oral amoxicillin-clavulanate 1 g twice a day for total of 6 doses
Study: NCT03508492

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Chloraprep® applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Chloraprep® applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Chloraprep® applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Chloraprep® applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Nex Clorex 2% applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Nex Clorex 2% applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Nex Clorex 2% applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Surgical tinted Nex Clorex 2% applicators
Description: We randomized knee, hip, cardiac and colon surgeons making them using two applicators of each brand in four of theirs surgeries. Randomization will be carried out in blocks of four for each surgeon.
Study: NCT03041558

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SafeCare+ (SC+)
Description: SafeCare intervention with the additional Healthy Relationships (HR) module

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: SafeCare (SC)
Description: SafeCare intervention as usual
Study: NCT02288585

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Plant sterols
Description: Plant sterols

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo product
Description: Placebo product
Study: NCT01820442

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine HCl
Description: Lofexidine HCl tablets titrated in ascending doses of 0.2 mg (1 tablet) QID starting at 0.4 mg (2 tablets) QID \[e.g. Day 1 0.4 mg (2 tablets) QID, Day 2 0.6 mg (3 tablets) QID, etc.\] as described in the treatment arm. Option to down-titrate to 0.2 mg (1 tablet) QID if 0.4 mg (2 tablets) QID dose not initially tolerated.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lofexidine-matching sugar pill
Description: Lofexidine-matching sugar pill tablets titrated in ascending doses of 1 tablet starting at 2 tablets QID (e.g. Day 1 2 tablets QID, Day 2 3 tablets QID, etc.) as described in the treatment arm. Option to down-titrate to 1 tablet QID if 2 tablets not initially tolerated.
Study: NCT03447158

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 15% Dextrose
Description: inject 15% dextrose and xylocaine into subacrominal bursa under sonographically guidance

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: inject normal saline and xylocaine into subacrominal bursa under sonographically guidance
Study: NCT02802605

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bemiparin
Description: Bemiparin subcutaneus administration
Study: NCT03303911

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytisine
Description: film-coated tablets; depending on arm assignment, 1 or 2 tablets to be taken with 240 mL water for each dose
Study: NCT02388568

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lorcaserin
Description: Lorcaserin plus Lifestyle Modification
Study: NCT04270279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xueshuanxinmaining tablet
Description: A kind of Chinese patent medicine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Xueshuanxinmaining placebo
Description: The simulant of Xueshuanxinmaining tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitroglycerin tablets
Description: Be used when angina attack

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitroglycerin tablets
Description: Be used when angina attack
Study: NCT01461109

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] CFPyPB
Description: Each subject will receive a bolus injection targeted to be 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of \[18F\]CFPyPB or 5 μg of CFPyPB (whichever is greatest).
Study: NCT02850471

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Transcutaneous Electric Acupoint Stimulation which is a device of electroacupuncture was used on patients in TEAS group with the stimulator parameters set as 2/100Hz, 2V, 30min.
Study: NCT02891070

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FS VH S/D 500 s-apr

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DuraSeal Dural Sealant
Study: NCT05282303

Intervention type: PROCEDURE
Intervention: CABG operation
Description: Efficacy of regional analgesia techniques in coronary artery bypass operations

Intervention type: PROCEDURE
Intervention: CABG operation
Description: Efficacy of regional analgesia techniques in coronary artery bypass operations

Intervention type: PROCEDURE
Intervention: CABG operation
Description: Efficacy of regional analgesia techniques in coronary artery bypass operations

Intervention type: PROCEDURE
Intervention: CABG operation
Description: Efficacy of regional analgesia techniques in coronary artery bypass operations
Study: NCT01701050

Intervention type: OTHER
Intervention: Blood collection
Description: Patients will have blood drawn for circulating tumor cell (CTC) endocrine therapy index (CTC-ETI) calculation at baseline (within 30 days prior to the initiation of endocrine therapy) and then subsequently 1, 2, 3 and up 12 months after the initiation of therapy, or at the time of disease progression, whichever occurs first.
Study: NCT03137745

Intervention type: OTHER
Intervention: thromboelastography
Description: thromboelastography was done pre HIPEC ,post HIPEC and first and second postoperative days
Study: NCT01784822

Intervention type: DEVICE
Intervention: Zenapro™ Hybrid Hernia Repair Device
Description: Device will be placed during open or laparoscopic hernia repair.
Study: NCT04308200

Intervention type: OTHER
Group type: OTHER
Intervention: CO-OP approach
Description: There are 3 stages in the CO-OP approach. Stage I, the Preparation Stage, is primarily concerned with establishing the goal. Before the first interview, the child was contacted, the family and the child were informed, and it was checked whether they met the prerequisites. At this stage, 3 targets were selected and the basic performance level was determined. Stage II, the Acquisition Stage, is essentially the plan and do stage, in which the work of using strategies to acquire skills is done. This stage originally comprised 10 sessions. At this stage, the first session enabling principles were implemented and the global strategy goal-plan-do-check was introduced. The family attended this process with observation. Parents / caregivers were encouraged to make observations to generalize strategies. Stage III, the Verificatíon stage usually consists of only one session in which control is performed; the progress made was revised as learned strategies.

Intervention type: OTHER
Group type: OTHER
Intervention: NDT
Description: All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.

Intervention type: OTHER
Group type: OTHER
Intervention: NDT
Description: All participations received NDT for 45 minutes once daily, two times a week for period of 6 weeks by the same physiotherapist. The NDT protocol is improving muscular tone and movement patterns. Although the treatment activities varied for each CP participant, the overall goals (improved smoothness and efficiency of movement), which included improved trunk, hip, knee and ankle control, were the same for all CP participants. All sessions incorporated handling techniques that aimed to alter muscle tone during movement and to facilitate anti-gravity, weight-shifting and postural reactions.
Study: NCT00795587

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: variation of mannitol dose
Description: in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: variation of mannitol dose
Description: in case of intracranial hypertension up to 20 mmHg lasting more than 10 minutes and without nociceptive stimulation or systemic instability: injection of either 0.4 g/ kg or 0.8 g/ kg of mannitol 20% (randomized) on 20 minutes, with monitoring of neurologic, systemic and biologic datas during 120 minutes
Study: NCT02205840

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SI-614
Description: 1 drop in each eye

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: 1 drop in each eye
Study: NCT02388568

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo plus Lifestyle Modification
Study: NCT04473417

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Forxiga
Description: single dose administration after 10hr fasting
Study: NCT03509012

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (dose level 1)
Description: IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (dose level 2)
Description: IV

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation (standard)
Description: radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation (standard)
Description: radiation therapy
Study: NCT04017845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tribenoside 400 mg + lidocaine 40 mg suppositories
Description: Treatment of hemorrhoids was initiated with tribenoside 400 mg + lidocaine 40 mg suppositories, once daily for up to 2 weeks.
Study: NCT05424055

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multicomponent exercise
Description: The intervention will consist of a multicomponent exercise training programme, which will include supervised progressive resistance exercise training, balance-training and walking for 3 consecutive days. During the training period, patients will be trained in 20-minute sessions twice a day (morning and evening). The supervised multicomponent exercise training programme will be comprised of upper and lower body strengthening exercises, tailored to the individual's functional capacity, using weight machines and aiming for 2-3 sets of 8-10 repetitions at an intensity of 40-60 % of 1RM (Matrix, Johnson Health Tech, Ibérica, S.L., Madrid, Spain) combined with balance and gait retraining exercises that will progress in difficulty and functional exercises, such as rises from a chair. The second part of the session will consist of functional exercises such as knee extension and flexion, hip abduction, balance movements, and daily walking in the hospital.
Study: NCT04017845

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment
Description: Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment
Description: Treatment of anal fissure was initiated with Diltiazem hydrochloride 2%/Nitroglycerin rectal ointment applied every 12 hours, for up to six weeks.
Study: NCT04548869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDX-0159
Description: Administered intravenously
Study: NCT03601884

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optimal Health Program
Description: The Optimal Health Program (OHP) is a self-management psychosocial program that promotes patients to be actively involved in their own healthcare and overall well-being. Sessions include Optimal Health, I-CAN-DO Model, Medication \& Metabolic Monitoring, Collaborative \& Strategies, Change enhancement, Visioning \& Goal Setting and Maintain Well-being.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Treatment as Usual
Description: Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients.

Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as Usual
Description: Treatment-as-usual TAU is the pharmacological treatment received or prescribed by the patients' attending doctor.~To ensure standardization of treatment, attending doctors will be reminded to manage patients in accordance with the Clinical practice Guideline in Managing Diabetes Melllitus in adult patients.
Study: NCT04055493

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribociclib 200Mg Oral Tablet
Description: 3 x 200 MG per os
Study: NCT02465268

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65-shLAMP DC with GM-CSF

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: unpulsed PBMC and saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Td
Description: All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Td
Description: All subjects will receive a Td booster before study drug dose #1. Subjects in the experimental arms will receive Td skin prep before study drug doses #3, #6, and #9.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: pp65-flLAMP DC with GM-CSF
Study: NCT05176132

Intervention type: OTHER
Intervention: Life style intervention (dietician+ physiotherapist)
Description: Obese patients with obesity related diseases will be invited to participate in a personalized lifestyle intervention program with dieticians and physiotherapists focusing on health improvement through personal motivation and perceived limitations and body accept.

Intervention type: OTHER
Intervention: Self management
Description: Patients with no obesity related diseases will not be offered lifestyle intervention, but encouraged to physical activity (self management)

Intervention type: OTHER
Intervention: No intervention
Description: Control groups (BMI 20-25 and BMI 25-30)